Tags

Type your tag names separated by a space and hit enter

Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
Front Immunol. 2020; 11:567710.FI

Abstract

The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines.

Authors+Show Affiliations

Solongevity Research, Milan, Italy.Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.Laboratory of Molecular Biology and Virology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33178193

Citation

Beretta, Alberto, et al. "Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?" Frontiers in Immunology, vol. 11, 2020, p. 567710.
Beretta A, Cranage M, Zipeto D. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis? Front Immunol. 2020;11:567710.
Beretta, A., Cranage, M., & Zipeto, D. (2020). Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis? Frontiers in Immunology, 11, 567710. https://doi.org/10.3389/fimmu.2020.567710
Beretta A, Cranage M, Zipeto D. Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis. Front Immunol. 2020;11:567710. PubMed PMID: 33178193.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis? AU - Beretta,Alberto, AU - Cranage,Martin, AU - Zipeto,Donato, Y1 - 2020/10/15/ PY - 2020/05/30/received PY - 2020/09/28/accepted PY - 2020/11/12/entrez PY - 2020/11/13/pubmed PY - 2020/11/13/medline KW - COVID-19 KW - SARS-CoV-2 KW - antibody-dependent enhancement KW - cross-reactivity KW - human coronaviruses KW - immunopathogenesis SP - 567710 EP - 567710 JF - Frontiers in immunology JO - Front Immunol VL - 11 N2 - The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/33178193/Is_Cross_Reactive_Immunity_Triggering_COVID_19_Immunopathogenesis L2 - https://doi.org/10.3389/fimmu.2020.567710 DB - PRIME DP - Unbound Medicine ER -